Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 40
- Registration Number
- NCT01891227
- Locations
- 🇦🇹
KH Barmh. Schwestern Linz, Innere Medizin I Hämatologie/Onkologie, Linz, Austria
🇦🇹Universitätsklinik f. Frauenheilkunde und Geburtshilfe, Klin. Abt. f. Gynäkologie, Graz, Austria
🇦🇹Hämatologie und Onkologie/Interne E, LKH Feldkirch, Feldkirch, Austria
Capecitabine With Digoxin for Metastatic Breast Cancer
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT01887288
- Locations
- 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT01880658
- Locations
- 🇨🇳
Gastrointestinal Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
- Conditions
- HER2-positive Breast CancerRecurrent Breast CancerStage IV Breast Cancer
- Interventions
- Drug: capecitabineDrug: cyclophosphamideDrug: lapatinib ditosylateBiological: trastuzumabOther: laboratory biomarker analysis
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 10
- Registration Number
- NCT01873833
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Phase II Trial for Large ER-Negative Breast Cancers
- Conditions
- Malignant Neoplasm of Female Breast
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 72
- Registration Number
- NCT01869192
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
- Conditions
- Cancer of Unknown Primary SiteBile Duct NeoplasmsGastrointestinal CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 59
- Registration Number
- NCT01845337
- Locations
- 🇬🇧
Edinburgh Cancer Centre, Edinburgh, Scotland, United Kingdom
A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer
- Conditions
- Oesophageal Cancer
- Interventions
- Drug: OxaliplatinDrug: CapecitabineRadiation: RadiotherapyDrug: CarboplatinDrug: PaclitaxelProcedure: Surgery
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- Lisette Nixon
- Target Recruit Count
- 85
- Registration Number
- NCT01843829
- Locations
- 🇬🇧
University Hospitals Coventry and Warwickshire, Coventry, United Kingdom
🇬🇧Bristol Oncology and Haematology Centre, Bristol, United Kingdom
🇬🇧Valindre NHS, Cardiff, United Kingdom
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
- Conditions
- Metastatic Gastric CancersMetastatic Colorectal CancersMetastatic Oesophageal CancersMetastatic Pancreatic CancersMetastatic Biliary CancersMetastatic Breast Cancers
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 37
- Registration Number
- NCT01843725
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal
- Conditions
- Carcinoma of Anal Canal
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 8
- Registration Number
- NCT01843452
- Locations
- 🇨🇭
Inselspital, Bern, Switzerland
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
- Conditions
- Pancreatic Carcinoma Non-resectableLocally Advanced Malignant NeoplasmPancreatic Cancer
- Interventions
- Drug: FOLFIRINOXRadiation: 5-FU ChemoradiationBiological: Algenpantucel-L ImmunotherapyDrug: GemcitabineDrug: CapecitabineDrug: Nab-Paclitaxel
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 302
- Registration Number
- NCT01836432
- Locations
- 🇺🇸
Sutter Institute for Medical Research, Sacramento, California, United States
🇺🇸USF Tampa General, Tampa, Florida, United States
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.